黑色素瘤软脑膜病变:尽管有新疗法,预后仍差
该回顾性研究纳入两个三级转诊皮肤癌中心2011年6月至2019年3月间52例黑色素瘤软脑膜病变(LMD)患者,评估其临床特征、诊断、治疗和总生存期(OS)。结果显示全队列中位OS为2.9个月(95%CI 1.7-4.1),接受系统治疗者OS为3.7个月(95%CI 2.4-4.9),提示靶向治疗或免疫检查点阻断可能改善OS,但总体预后仍差。
要点
- 黑色素瘤LMD患者中位OS仅2.9个月(95%CI 1.7-4.1)。
- 接受系统治疗(靶向或免疫检查点阻断)者中位OS为3.7个月(95%CI 2.4-4.9)。
- 多数患者(85%)诊断LMD时有临床症状,69%合并脑转移。
核心结论
- 靶向治疗或免疫检查点阻断的系统治疗似乎可改善黑色素瘤LMD患者的总生存期。
- 尽管采用了新的治疗方式,LMD患者的预后仍然很差。
研究设计与样本
- 回顾性研究,纳入两个三级转诊皮肤癌中心2011年6月至2019年3月间52例黑色素瘤LMD患者。
主要发现
- 全队列中位OS为2.9个月(95%CI 1.7-4.1)。
- 接受系统治疗的患者中位OS为3.7个月(95%CI 2.4-4.9)。
- 从首次诊断不可切除疾病至首次诊断LMD的中位时间为8.5个月(范围0-91.5个月)。
- 65%(n=34)患者为BRAF V600突变;69%(n=36)诊断LMD时合并脑转移;21%(n=11)无颅外疾病证据。
临床怎么用
- 对于黑色素瘤LMD患者,可考虑使用靶向治疗或免疫检查点阻断等系统治疗以可能改善生存。
- 诊断LMD时需注意多数患者有临床症状且常合并脑转移,应结合临床与影像学及时评估。
局限性
- 回顾性研究设计,样本量有限(52例),可能存在选择偏倚。
- 患者来自两个三级转诊中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The development of leptomeningeal disease (LMD) among melanoma patients is associated with short survival. Unspecific clinical symptoms and imprecise diagnostic criteria often delay diagnosis. Because melanoma patients with LMD have been excluded from most clinical trials, the efficacy of immune checkpoint blockade (ICB) and targeted therapies (TTs) has not been adequately investigated among these patients. METHODS: We performed a retrospective study in two tertiary-referral skin cancer centres to evaluate the clinical characteristics, diagnostics, treatments, and overall survival (OS) of melanoma patients with LMD between June 2011 and March 2019. RESULTS: In total, 52 patients were included. The median age at LMD diagnosis was 58 years. Most patients (n = 30, 58%) were men. The median time from the first diagnosis of unresectable disease to the first diagnosis of LMD was 8.5 months (range 0-91.5 months). Most patients (65%, n = 34) were BRAF V600 mutated. Sixteen patients (31%) presented with LMD only, whereas 36 patients (69%) presented with concomitant brain metastases at LMD diagnosis. Eleven patients (21%) showed no evidence of extracranial disease. Forty-four patients (85%) had clinical symptoms at LMD diagnosis. Forty-two patients (81%) had received at least one prior therapy. Forty patients (77%) received at least one treatment after LMD diagnosis, including TT (n = 17), ICB (n = 13), bevacizumab (n = 1), radiotherapy (n = 3), and intrathecal chemotherapy (n = 1); five patients received both TT and ICB. Twelve patients (23%) received no treatment because of rapid progression of LMD. The median OS for the entire cohort was 2.9 months (95% confidence interval [CI] 1.7-4.1). Among patients receiving systemic therapy, OS was 3.7 months (95% CI 2.4-4.9). CONCLUSIONS: Systemic treatment with TT or ICB seems to improve OS among patients with LMD. However, despite new therapy modalities, the prognosis of LMD remains poor.
引用
- Chorti E, Kebir S, Ahmed MS, et al. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. Eur J Cancer. 2021. PMID: 33789203. doi:10.1016/j.ejca.2021.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。